TMCnet News
Reflect Scientific Introduces PF-90 Blast Plate Freezer, Combining Two Freezing Technologies for Biopharmaceutical and Cell Therapy ApplicationsOREM, Utah, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), through its Cryometrix brand, today announced the launch of the PF-90 Blast Plate Freezer, a next-generation ultra-low temperature system engineered to combine liquid nitrogen (LN2) blast freezing with conductive plate freezing in a single unit. The PF-90 is designed for facilities handling biopharmaceuticals, biologics, vaccines, plasma, blood products, cell and gene therapy materials, pharmaceutical drug substances, and other bioprocessing materials that require rapid, uniform, and repeatable freezing. The PF-90 is patent pending. Two Freezing Methods, One System Historically, facilities have had to choose between blast freezers, which use high-velocity ultra-cold air and are well suited to mixed or irregularly shaped loads, and plate freezers, which use direct-contact cooling plates on specific bag types to achieve uniform, flat-frozen bags. The PF-90 eliminates that tradeoff by integrating both technologies into a single platform, allowing operators to select the optimal method for each application while reducing capital costs, floor space requirements, and operational complexity. “Plate freezing has become a necessary method for many biologics and blood product applications because it delivers faster heat transfer, improved uniformity across bag thickness, and reduced ice crystal formation,” the company noted, pointing to the reproducibility that regulated environments require. Key Specifications
The PF-90's cooling system is powered by Cryometrix's proprietary LN2 technology, which does not rely on compressors or circulated refrigerants. The company states this design reduces common mechanical failure points, lowers electrical demand compared to compressor-based systems, and reduces heat output to surrounding HVAC infrastructure. Target Applications The PF-90 is intended for use in biopharmaceutical manufacturing, blood banking and transfusion centers, cell and gene therapy facilities, and research laboratory environments where even small variations in freezing conditions can affect product integrity and regulatory compliance. Market Context Demand for ultra-low temperature freezing equipment continues to grow alongside expansion in biologics, cell and gene therapy, and blood product processing. Industry research estimates the global blast freezer market at $1.84 billion in 2025, growing to approximately $1.94 billion in 2026, and projected to reach $2.58 billion by 2032 at a compound annual growth rate of 4.89%. Separately, the global biomedical refrigerator and freezer market has been estimated at $4.34 billion in 2025, growing to approximately $4.8 billion in 2026 at a compound annual growth rate of 10.6%, with growth attributed in part to expanding vaccine storage needs, blood and plasma storage requirements, and temperature-controlled drug development activity. Market size estimates vary by research firm and market definition, and figures should be considered directional rather than authoritative. Availability Pricing for the PF-90 is available upon request. Interested parties can contact Cryometrix directly at (801) 226-4100 or [email protected]. About Reflect Scientific, Inc. Reflect Scientific, Inc., based in Orem, Utah, develops and markets innovative, proprietary technologies in cryogenic cooling for the biotechnology, pharmaceutical, medical, and transportation markets. Among Reflect Scientific’s products are low-temperature freezers and refrigerated systems for laboratory, transportation, and computer server room uses. Visit reflectscientific.com for more information. See us on Twitter @ReflectSci and LinkedIn www.linkedin.com/company/reflect-scientific. Forward-Looking Statements  Contact Investor Relations 801-607-1039 [email protected]
|
